Portfolio

Company Announcements

Rule 2.9 Announcement

Related Companies

By LSE RNS

RNS Number : 8238S
Clinigen Group plc
05 October 2017
 

5 October 2017

 

Rule 2.9 Announcement

In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, Clinigen Group plc (the "Company") confirms that, as at the date of this announcement, its issued share capital consists of

115,369,132 ordinary shares of 0.1 pence each with International Securities Identification Number GB00B89J2419. The Company holds no shares in treasury.

 

 

-Ends-

 

Contact details

 

Clinigen Group plc

Tel: +44 (0) 1283 495010

Shaun Chilton, Group Chief Executive Officer


Martin Abell, Group Chief Financial Officer




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Tom Ballard  (Corporate Broking)




RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas / Jack Wood




Instinctif Partners

Tel: +44 (0) 20 7457 2020

Adrian Duffield / Melanie Toyne-Sewell / Alex Shaw

Email: clinigen@instinctif.com

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

 

For more information, please visit www.clinigengroup.com 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RTTEAEESEFSXFFF

Top of Page